143 related articles for article (PubMed ID: 11779297)
1. Durable remission in recurrent T-cell-rich B-cell lymphoma with the anti-CD20 antibody rituximab.
Natkunam Y; Stanton TS; Warnke RA; Horning SJ
Clin Lymphoma; 2001 Dec; 2(3):185-7. PubMed ID: 11779297
[TBL] [Abstract][Full Text] [Related]
2. CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.
Pijuan L; Vicioso L; Bellosillo B; Ferrer MD; Baró T; Pedro C; Lloreta-Trull J; Munné A; Serrano S
Am J Surg Pathol; 2005 Oct; 29(10):1399-403. PubMed ID: 16160485
[TBL] [Abstract][Full Text] [Related]
3. T-cell-rich B-cell non-Hodgkin's lymphoma mimicking Hodgkin's disease.
Bättig B; Mueller-Garamvoelgyi E; Cogliatti SB; Schmid U; Kappeler A; Cerny T; Laissue JA; Fey MF
Leuk Lymphoma; 1999 Apr; 33(3-4):393-8. PubMed ID: 10221522
[TBL] [Abstract][Full Text] [Related]
4. Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy.
Maeshima AM; Taniguchi H; Nomoto J; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Matsuno Y
Cancer Sci; 2009 Jan; 100(1):54-61. PubMed ID: 19038008
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD20 monoclonal antibody (Rituximab) for therapy of mediastinal CD20-positive large B-cell non-Hodgkin lymphoma with a local tumor extension into the lung of a 10-year-old girl.
Culić S; Culić V; Armanda V; Kuljis D; Pesutić-Pisac V; Janković S
Pediatr Hematol Oncol; 2003 Jun; 20(4):339-44. PubMed ID: 12746167
[TBL] [Abstract][Full Text] [Related]
6. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.
Alvaro-Naranjo T; Jaén-Martínez J; Gumá-Padró J; Bosch-Príncep R; Salvadó-Usach MT
Ann Hematol; 2003 Sep; 82(9):585-8. PubMed ID: 12898184
[TBL] [Abstract][Full Text] [Related]
7. T-cell-rich B-cell lymphoma and lymphocyte-predominant Hodgkin's disease: two closely related entities?
Schmidt U; Metz KA; Leder LD
Br J Haematol; 1995 Jun; 90(2):398-403. PubMed ID: 7794762
[TBL] [Abstract][Full Text] [Related]
8. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
[TBL] [Abstract][Full Text] [Related]
9. Rituximab monotherapy in nodular lymphocyte-predominant Hodgkin's disease.
Boulanger E; Meignin V; Leverger G; Solal-Céligny P
Ann Oncol; 2003 Jan; 14(1):171. PubMed ID: 12488312
[No Abstract] [Full Text] [Related]
10. [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
Al-Ali HK; Wittekind C; Niederwieser D
Dtsch Med Wochenschr; 2007 Aug; 132(33):1688-91. PubMed ID: 17713864
[TBL] [Abstract][Full Text] [Related]
11. Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review.
Kennedy GA; Tey SK; Cobcroft R; Marlton P; Cull G; Grimmett K; Thomson D; Gill D
Br J Haematol; 2002 Nov; 119(2):412-6. PubMed ID: 12406079
[TBL] [Abstract][Full Text] [Related]
12. Dramatical improvement of chemoresistant bone lymphoma with rituximab.
Achemlal L; Mikdame M; Nouijai A; Bezza A; El Maghraoui A
Clin Rheumatol; 2006 May; 25(3):394-5. PubMed ID: 16247586
[TBL] [Abstract][Full Text] [Related]
13. Histiocyte-rich, T-cell-rich B-cell lymphoma: a distinct diffuse large B-cell lymphoma subtype showing characteristic morphologic and immunophenotypic features.
Achten R; Verhoef G; Vanuytsel L; De Wolf-Peeters C
Histopathology; 2002 Jan; 40(1):31-45. PubMed ID: 11903596
[TBL] [Abstract][Full Text] [Related]
14. Rituximab in combination with vinorelbine/gemcitabine chemotherapy in patients with primary refractory or early relapsed T cell rich B cell lymphoma. A pilot study.
Xiros N; Economopoulos T; Valsami S; Rontogianni D; Fountzilas G; Raptis S
Leuk Res; 2003 Dec; 27(12):1097-9. PubMed ID: 12921946
[TBL] [Abstract][Full Text] [Related]
15. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma.
Anderson DR; Grillo-López A; Varns C; Chambers KS; Hanna N
Biochem Soc Trans; 1997 May; 25(2):705-8. PubMed ID: 9191187
[No Abstract] [Full Text] [Related]
16. Intralesional rituximab for cutaneous B-cell lymphoma.
Paul T; Radny P; Kröber SM; Paul A; Blaheta HJ; Garbe C
Br J Dermatol; 2001 Jun; 144(6):1239-43. PubMed ID: 11422050
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of primary cardiac lymphoma with monoclonal CD20 antibody (rituximab).
Nakagawa Y; Ikeda U; Hirose M; Ubukata S; Katsuki TA; Kaminishi Y; Saito T; Hironaka M; Izumi T; Shimada K
Circ J; 2004 Feb; 68(2):172-3. PubMed ID: 14745155
[TBL] [Abstract][Full Text] [Related]
18. CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy.
Massengale WT; McBurney E; Gurtler J
J Am Acad Dermatol; 2002 Mar; 46(3):441-3. PubMed ID: 11862185
[TBL] [Abstract][Full Text] [Related]
19. Enhanced therapeutic effect of B cell-depleting anti-CD20 antibodies upon combination with in-situ dendritic cell vaccination in advanced lymphoma.
Manzur S; Cohen S; Haimovich J; Hollander N
Clin Exp Immunol; 2012 Dec; 170(3):291-9. PubMed ID: 23121670
[TBL] [Abstract][Full Text] [Related]
20. The use of ibritumomab tiuxetan radioimmunotherapy for patients with relapsed B-cell non-Hodgkin's lymphoma.
Witzig TE
Semin Oncol; 2000 Dec; 27(6 Suppl 12):74-8. PubMed ID: 11226003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
